*Q4 below expectations* Languishing Alcon and flat Sandoz slowed Q4 sales growth to 4% (vs 6% in Q3) in cc (all revenue growth numbers in cc unless specified). Strong dollar against most currencies wiped out 8% points from top-line, which came in 4% lower at reported level to $12.5bn for the quarter. For the full year, net sales (from continuing operations) grew by 5% to $49.4bn, which was slightly behind our estimate of $50.2bn. Unfavourable currency impact of 10% pulled down reported growth
02 Feb 2016
Gleevec erosion and Alcon weakness to weigh on H1 2016
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Gleevec erosion and Alcon weakness to weigh on H1 2016
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
02 Feb 2016 -
Author:
Kamla Singh -
Pages:
3
*Q4 below expectations* Languishing Alcon and flat Sandoz slowed Q4 sales growth to 4% (vs 6% in Q3) in cc (all revenue growth numbers in cc unless specified). Strong dollar against most currencies wiped out 8% points from top-line, which came in 4% lower at reported level to $12.5bn for the quarter. For the full year, net sales (from continuing operations) grew by 5% to $49.4bn, which was slightly behind our estimate of $50.2bn. Unfavourable currency impact of 10% pulled down reported growth